Choriogonadotropin alfa and Ethynodiol diacetate and ethinyl estradiol interaction
Choriogonadotropin alfa and Ethynodiol diacetate and ethinyl estradiol: the Choriogonadotropin alfa prescribing label describes an interaction that usually calls for monitoring, a dose change, or spacing the doses.
Usually manageable with monitoring or a dose change. Tell your pharmacist you take both.
What the FDA labels say
From the Choriogonadotropin alfa (Pregnyl) label · effective 2025-12-02
Safe and effective induction of ovulation with use of PREGNYL requires monitoring of ovarian response with serum estradiol and transvaginal ultrasound on a regular basis.
The combination of both pelvic ultrasound and serum estradiol measurement are useful for monitoring the development of follicles, for timing of the ovulatory trigger, as well as for detecting ovarian enlargement and minimizing the risk of the Ovarian Hyperstimulation Syndrome and multiple gestation.
This may be estimated by pelvic ultrasound alone or in combination with measurement of serum estradiol levels.
Confirm the number of growing follicles using ultrasonography because serum estrogens do not give an indication of the size or number of follicles.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.